The Global Diabetes Injection Pens Market was valued at USD 13.81 Billion in 2020 and is projected to reach USD 17.78 Billion by 2029, growing at a CAGR of 7.45% from 2021 to 2029.
Diabetes Injection Pens Market Overview
Diabetes insulin pens are advanced versions of prefilled insulin syringes and pen needles that are used to inject insulin into the bodies of type 1 diabetes patients. These pens typically include an insulin cartridge that serves as an insulin reservoir and a dial that allows the user to precisely measure the amount of insulin to be delivered to the patient. These cartridges and pens come in a variety of shapes and sizes, as well as disposable and non-disposable varieties. The majority of diabetes pens include replaceable, thin, and extremely short insulin pen needles to reduce pain during injection.
There are also universal pen needles on the market that fit almost all brands of insulin pens. These pens are convenient, easy to transport, and can be used in the home to provide accurate dose delivery. As a result, the demand for diabetes insulin pens is increasing.
Diabetes injection pens are available for purchase at hospitals, pharmacies, diabetes centers and clinics, retail pharmacies, and online. Purchasing injection pens from hospitals is the most preferred distribution channel, accounting for more than 33.0 percent of the global diabetes injection pens market in 2015. The online channel is becoming much more visible as a result of the availability of a thriving global e-commerce sector. However, because the use of diabetes injection pens in hospitals is increasing in developed markets such as Germany, the United Kingdom, and the United States, this segment is expected to grow rapidly over the forecast period.
Diabetes pens are in high demand due to the rising prevalence of the disease. Diabetes pens are used in conjunction with the growing demand for insulin pens among diabetics. These devices, which are used in conjunction with insulin pens, aid in the administration of the drug to the subject. Huge technological advancements are also propelling the Diabetes pen industry forward. Companies are concentrating on the development of new needle length products. Diabetes pen needles with shorter lengths can be easily used by all patients, including those who are overweight. These factors are expected to drive the growth of the Global Diabetes Pen Market.
Certain constraints and limitations are being faced, which will impede overall market growth. Factors such as the inability of two types of insulin to be mixed in an insulin pen increase the frequency of injections required. As a result, the market's growth is stifled. Furthermore, preference for alternative modes of drug delivery, as well as a poor reimbursement scenario in developing countries, are potential restraints to the overall growth of the Global Diabetes Pen Market. Nonetheless, technological advancements, a growing preference for biosimilar drugs, and untapped potential in emerging markets provide beneficial growth opportunities.
What is our Diabetes Injection Pens Market Report Scope?
|
Report Attributes
|
Report Details
|
|
Forecast Period 2022 to 2029 CAGR
|
CAGR of 7.45% during the review period (2022 to 2029).
|
|
By Type
|
- Disposable Injection Pens
- Reusable Injection Pens
|
|
By Application
|
- Diabetes
- Growth Hormone
- Osteoporosis
- Fertility
- Auto-immune Diseases
- Cancer
- Other Therapies
|
|
By End User
|
- Home-care Settings
- Hospitals & Diagnostic Clinics
|
|
By Companies
|
Novo Nordisk A/S (Denmark), Becton, Dickinson and Company (US), Ypsomed Holding AG (Switzerland), Sanofi (France), Eli Lilly and Company (US), Merck KGaA (Germany), AstraZeneca plc (UK), F. Hoffmann-La Roche Ltd. (Switzerland), Owen Mumford (UK)
|
|
Regions Covered
|
- North America
- Europe
- Asia-Pacific
- Rest of the World
|
|
Countries Covered
|
- US
- Canada
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East & Africa
- Latin America
|
|
Base Year
|
2022
|
|
Historical Year
|
2017 to 2021
|
|
Forecast Year
|
2022 to 2029
|
|
Number of Pages
|
133
|
|
Customization Available
|
Yes, the report can be customized as per your needs
|
Who are the Major Players in Diabetes Injection Pens Market?
Major players operating in the global neurological biomarkers market include Novo Nordisk A/S (Denmark), Becton, Dickinson and Company (US), Ypsomed Holding AG (Switzerland), Sanofi (France), Eli Lilly and Company (US), Merck KGaA (Germany), AstraZeneca plc (UK), F. Hoffmann-La Roche Ltd. (Switzerland), Owen Mumford (UK), Sulzer Ltd. (Switzerland), Sun Pharmaceutical Industries Ltd. (India), Pfizer (US), Biocon Ltd. (India), Lupin Ltd. (India), Wockhardt Ltd. (India), AptarGroup, Inc. (US), Novartis AG (Switzerland), Gerresheimer AG (Germany), Bespak Europe Ltd. (UK), SHL Medical AG (Switzerland), Boehringer Ingelhem (Germany), Nemera France SA, Companion Medical (US), and Jiangsu Delfu Medical Devices Co., Ltd. (China).
Recent Developments
Partnerships, Collaborations, and Agreements
• In April 2021, mySugr announced the integration of the Novo Nordisk NovoPen 6® and NovoPen Echo® Plus into the mySugr Logbook on iOS. The integration follows the collaboration agreement signed between Roche and Novo Nordisk in 2019.
Mergers and Acquisitions
• On August 2020, Medtronic plc (NYSE: MDT), the global leader in medical technology, announced the planned acquisition of privately-held Companion Medical, manufacturer of InPen — the only U.S. FDA-cleared smart insulin pen system paired with an integrated diabetes management app on the market.
Product Launches and Product Expansions
• On May 2021, BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its board of directors has unanimously authorized management to proceed with a plan to spin off the company’s Diabetes Care business as an independent, publicly-traded company (“NewCo”).
• In November 2020, Medtronic plc the global leader in medical technology, announced the launch of InPen™ integrated with real-time1 Guardian Connect™ CGM data. InPen is the first and only FDA-cleared smart2 insulin pen on the market for people on multiple daily injections (MDI).
• In August 2019, Astra Zeneca announced that the European Commission (EC) has approved Bydureon BCise (exenatide 2mg prolonged-release suspension for injection in pre-filled pen) as a new formulation within the marketing authorisation for Bydureon (exenatide extended-release) for the treatment of patients with type-2 diabetes.
Diabetes Injection Pens Market Segmentation
Diabetes Injection Pens Market, by Product Type
- Disposable Injection Pens
- Reusable Injection Pens
Diabetes Injection Pens Market, by Therapy
- Diabetes
- Insulin therapy
- GLP-1 therapy
- Growth Hormone
- Osteoporosis
- Fertility
- Auto-immune Diseases
- Cancer
- Other Therapies
Diabetes Injection Pens Market, by End User
- Home-care Settings
- Hospitals & Diagnostic Clinics
Diabetes Injection Pens Market Regional Analysis
The Global Diabetes Injection Pens Market is classified into North America, Europe, Asia Pacific, and Rest of the world. North America holds the largest market share. The growing diabetes prevalence and favorable reimbursement scenario for pen needles, federal initiatives to create awareness about injection techniques, increasing market penetration by leading players, the development of improved pen needle technologies, and ongoing projects will boost the market in the North American region.
In 2020, North America dominated the global injection pens market. The large share of the North American injection pens market can primarily be attributed to the rising prevalence of diabetes, favorable reimbursement scenario, and the increasing number of awareness progr
- North Amerika
- Europe
- U.K.
- Germany
- France
- Italy
- Spain
- Asia Pacific
- India
- China
- Japan
- Australia
- South Korea
- Latin America
- Middle East & Africa
- Saudi Arabia
- UAE
- South Africa
- INTRODUCTION
- MARKET DEFINATION
- MARKET DYNAMICS
- MARKET SEGMENTATION
- REPORT TIMLINES
- KEY STAKEHOLDERS
- RESEARCH METHODOLOGY
- DATA MINING
- SECONDARY RESEARCH
- PRIMARY RESEARCH
- SUBJECT MATTER EXPERT ADVICE
- QUALITY CHECK
- FINAL REVIEW
- DATA TRIANGULATION
- BOTTOM-UP APPROACH
- TOP-DOWN APPROACH
- RESEARCH FLOW
- EXECUTIVE SUMMARY
- INTRODUCTION
- GLOBAL DIABETES INJECTION PENS MARKET BY TYPES
- GLOBAL DIABETES INJECTION PENS MARKET BY APPLICATIONS
- MARKET DYNAMICS
- DRIVERS
- INCREASING GERIATRIC POPULATION AND PREVALENCE OF CHRONIC DISEASE
- RESTRAINTS
- STRINGENT ENVIRONMENTAL REGUALTIONS
- HIGH COST ON MATERIALS
- OPPORTUNITIES
- DIABETES INJECTION PENS GROWTH
- APPLICATION OF DIABETES INJECTION PENS IMPACT OF COVID 19
- GLOBAL DIABETES INJECTION PENS MARKET, BY TYPE
- DISPOSABLE INJECTION PENS
- REUSABLE INJECTION PENS
- GLOBAL DIABETES INJECTION PENS MARKET, BY APPLICATION
- DIABETES
- GROWTH HORMONE
- OSTEOPOROSIS
- FERTILITY
- AUTO-IMMUNE DISEASES
- CANCER
- OTHER THERAPIES
- GLOBAL DIABETES INJECTION PENS MARKET, BY REGION
- NORTH AMERICA
- EUROPE
- GERMANY
- FRANCE
- UK
- ITALY
- RUSSIA
- REST OF EUROPE
- APAC
- CHINA
- SOUTH KOREA
- JAPAN
- INDIA
- AUSTRALIA
- ASEAN
- REST OF APAC
- MIDDLE EAST & AFRICA
- SAUDI ARABIA
- UAE
- SOUTH AFRICA
- TURKEY
- REST OF MEA
- SOUTH AMERICA
- BRAZIL
- REST OF MEA
- ARGENTINA
- REST OF SOUTH AMERICA
- COMPETITIVE LANDSCAPE
- MERGERS, ACQUISITIONS, JOINT VENTURES, COLLABORATIONS,
- AND AGREEMENTS
- MARKET SHARE PERCENT /RANKING ANALYSIS
- STRATEGIES ADOPTED BY LEADING PLAYERS
- COMPANY PROFILES
- BUSINESS OVERVIEW
- COMPANY SNAPSHOT
- PRODUCT BENCHMARKING
- STRATEGIC INITIATIVES
- NOVO NORDISK A/S (DENMARK)
- BECTON, DICKINSON AND COMPANY (US)
- YPSOMED HOLDING AG (SWITZERLAND)
- SANOFI (FRANCE)
- ELI LILLY AND COMPANY (US)
SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.
PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.
MARKET ENGINEERING
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.
EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.
REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.
